Psoriasis is one of those conditions that looks deceptively simple – a rash that comes and goes – but is actually a systemic immune condition with effects well beyond the skin. For a child or teenager, the visible nature of psoriasis plaques on the face, scalp, or limbs carries a psychological weight that most adults around them underestimate. The condition affects participation in swimming, sports, and social activities in ways that accumulate over years.
Understanding what psoriasis is, what triggers flares, and what treatments are now available – including newer biologic agents that have transformed the management of severe disease in young people – helps parents advocate effectively for their child.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers chronic skin conditions in children.
What Psoriasis Is
Psoriasis is an autoimmune condition in which T lymphocytes drive excessive and rapid skin cell turnover: skin cells that normally take around 28 days to mature and shed are replaced in 3-7 days in psoriatic skin. This pile-up of immature cells creates the characteristic plaques. The condition is chronic and relapsing, with periods of flare followed by remission. It is not contagious.
There is a strong genetic component: about one-third of people with psoriasis have a first-degree relative with the condition. Several susceptibility loci have been identified, with HLA-Cw6 conferring the strongest genetic risk.
Types in Children
Plaque psoriasis is the most common type in all ages, including children. Well-defined, raised, red patches covered with silvery-white scale appear on the elbows, knees, lower back, and scalp. Nails can be affected (pitting, onycholysis, oil drop changes) – nail psoriasis is seen in around 40-80% of adults with psoriasis and is less common but present in children.
Guttate psoriasis is particularly common in children and adolescents. It appears as numerous small (0.5-1.5cm) teardrop-shaped pink spots scattered across the trunk and limbs, often following a streptococcal throat infection. Nick Reynolds and colleagues have established the link between Group A Streptococcus infection and guttate flares. The condition often resolves spontaneously within weeks to months and may not recur, though a proportion of guttate psoriasis cases evolve into chronic plaque psoriasis.
Scalp psoriasis is common and particularly distressing for children, who may have visible flaking that is mistaken for severe dandruff. The plaques can extend beyond the hairline.
Flexural (inverse) psoriasis occurs in the skin folds: nappy area in babies and young children, armpits, groin, under the breasts. It lacks the typical silvery scale because moisture in these areas prevents scale formation.
Common Triggers
Streptococcal throat infections are the most significant trigger in children, particularly for guttate psoriasis. Stress, skin injury (Koebner phenomenon – psoriasis appearing at sites of skin trauma), certain medications (beta-blockers, lithium, NSAIDs), and hormonal changes can all trigger or worsen psoriasis. Smoking and obesity are associated with more severe disease in adults; obesity is increasingly recognised as a risk factor in adolescents too.
Treatment
Topical treatments are first-line. Emollients reduce scaling and dryness; they should be used daily regardless of flare activity. Topical corticosteroids reduce inflammation during flares: mild potency (such as 1% hydrocortisone) is used on the face and flexures; moderate to potent steroids on the body and scalp (used intermittently to minimise side effects). Vitamin D analogues (calcipotriol) work differently and are used alone or in combination with a topical corticosteroid (the combination product Dovobet contains both). Coal tar preparations remain useful, particularly for scalp involvement, though they are messy and less acceptable to teenagers.
Phototherapy (narrow-band UVB) is used for widespread or moderate disease not responding to topicals. It requires regular clinic attendance (typically three times weekly) and is not practical for all families.
Systemic treatments for moderate-to-severe psoriasis in children include methotrexate (most commonly used), ciclosporin (short-term only due to nephrotoxicity), and acitretin (a retinoid, not appropriate for girls of childbearing potential because of teratogenicity).
Biologics have transformed the management of severe paediatric psoriasis in the last decade. Adalimumab (an anti-TNF biologic) is licensed from age 4 for severe chronic plaque psoriasis. Secukinumab (anti-IL-17A) is licensed from age 6, and ixekizumab from age 6. These agents produce clear or almost clear skin in the majority of patients with severe disease and have changed the prognosis for children with previously intractable psoriasis. NICE NG6 provides guidance on when to consider biologics.
Psychological Impact
The impact of psoriasis on children's quality of life is consistently underestimated in clinical practice. Studies using the Children's Dermatology Life Quality Index (CDLQI) have shown that psoriasis has a comparable or greater impact on daily life than conditions routinely taken seriously, such as type 1 diabetes. Children with psoriasis have higher rates of anxiety, depression, and peer difficulties. Self-consciousness about visible plaques is a major source of distress, particularly in teenagers.
Referral to a clinical psychologist should be a routine part of care for children with moderate-to-severe psoriasis, not an afterthought.
Key Takeaways
Psoriasis is a chronic inflammatory skin condition affecting approximately 1-2% of the UK population, with about one-third of cases beginning in childhood. It causes well-defined red plaques covered with silvery scales, most commonly on the elbows, knees, and scalp. Psoriasis in children is managed differently to adult psoriasis: topical treatments are first-line, systemic treatments and biologics (such as adalimumab, licensed for children with severe plaque psoriasis from age 4) are reserved for moderate-to-severe disease. Psoriasis has a significant impact on quality of life and is associated with anxiety and depression in children and adolescents. NICE guideline NG6 provides UK treatment guidance.
